159 related articles for article (PubMed ID: 35849520)
1. Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients.
Walti CS; Stuehler C; Palianina D; Khanna N
Curr Opin Infect Dis; 2022 Aug; 35(4):302-311. PubMed ID: 35849520
[TBL] [Abstract][Full Text] [Related]
2. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
Pfeiffer T; Tzannou I; Wu M; Ramos C; Sasa G; Martinez C; Lulla P; Krance RA; Scherer L; Ruderfer D; Naik S; Bocchini C; Fraser IP; Patel B; Ward D; Wang T; Heslop HE; Leen AM; Omer B
Clin Cancer Res; 2023 Jan; 29(2):324-330. PubMed ID: 36628536
[TBL] [Abstract][Full Text] [Related]
3. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
4. Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation.
Heinz AT; Calkoen FGJ; Derbich A; Miltner L; Seitz C; Doering M; Braun C; Atar D; Schumm M; Heubach F; Arendt AM; Schulz A; Schuster FR; Meisel R; Strahm B; Finke J; Heineking B; Stetter S; Silling G; Stachel D; Gruhn B; Debatin KM; Foell J; Schulte JH; Woessmann W; Mauz-Körholz C; Tischer J; Feuchtinger T; Handgretinger R; Lang P
Haematologica; 2023 Aug; 108(8):2080-2090. PubMed ID: 36794500
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT
Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288
[TBL] [Abstract][Full Text] [Related]
6. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
7. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
8. Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.
Gopcsa L; Réti M; Andrikovics H; Bobek I; Bekő G; Bogyó J; Ceglédi A; Dobos K; Giba-Kiss L; Jankovics I; Kis O; Lakatos B; Mathiász D; Meggyesi N; Miskolczi G; Németh N; Paksi M; Riczu A; Sinkó J; Szabó B; Szilvási A; Szlávik J; Tasnády S; Reményi P; Vályi-Nagy I
Geroscience; 2024 Feb; 46(1):1083-1106. PubMed ID: 37414968
[TBL] [Abstract][Full Text] [Related]
9. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
Linn YC; Sundar Raj K; Teo B; Phang CY; Chittezhath M; Koh M
Cytotherapy; 2023 May; 25(5):510-520. PubMed ID: 36882347
[TBL] [Abstract][Full Text] [Related]
10. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.
Hill JA; Mayer BT; Xie H; Leisenring WM; Huang ML; Stevens-Ayers T; Milano F; Delaney C; Sorror ML; Sandmaier BM; Nichols G; Zerr DM; Jerome KR; Schiffer JT; Boeckh M
Blood; 2017 Apr; 129(16):2316-2325. PubMed ID: 28209721
[TBL] [Abstract][Full Text] [Related]
11. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD; Hanley PJ; Chi YY; Aguayo-Hiraldo P; Dvorak CC; Verneris MR; Kohn DB; Pai SY; Dávila Saldaña BJ; Hanisch B; Quigg TC; Adams RH; Dahlberg A; Chandrakasan S; Hasan H; Malvar J; Jensen-Wachspress MA; Lazarski CA; Sani G; Idso JM; Lang H; Chansky P; McCann CD; Tanna J; Abraham AA; Webb JL; Shibli A; Keating AK; Satwani P; Muranski P; Hall E; Eckrich MJ; Shereck E; Miller H; Mamcarz E; Agarwal R; De Oliveira SN; Vander Lugt MT; Ebens CL; Aquino VM; Bednarski JJ; Chu J; Parikh S; Whangbo J; Lionakis M; Zambidis ET; Gourdine E; Bollard CM; Pulsipher MA
Nat Commun; 2024 Apr; 15(1):3258. PubMed ID: 38637498
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
13. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy with virus-specific T cells.
Fuji S; Kapp M; Grigoleit GU; Einsele H
Best Pract Res Clin Haematol; 2011 Sep; 24(3):413-9. PubMed ID: 21925094
[TBL] [Abstract][Full Text] [Related]
15. Applications of virus-specific T cell therapies post-BMT.
Motta CM; Keller MD; Bollard CM
Semin Hematol; 2023 Jan; 60(1):10-19. PubMed ID: 37080705
[TBL] [Abstract][Full Text] [Related]
16. Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34
Huang YT; Kim SJ; Lee YJ; Burack D; Nichols P; Maloy M; Perales MA; Giralt SA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1759-1766. PubMed ID: 28668490
[TBL] [Abstract][Full Text] [Related]
17. Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.
Baugh KA; Tzannou I; Leen AM
Curr Opin Infect Dis; 2018 Aug; 31(4):292-300. PubMed ID: 29750672
[TBL] [Abstract][Full Text] [Related]
18. Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients.
Schulze Lammers FC; Bonifacius A; Tischer-Zimmermann S; Goudeva L; Martens J; Lepenies B; von Karpowitz M; Einecke G; Beutel G; Skripuletz T; Blasczyk R; Beier R; Maecker-Kolhoff B; Eiz-Vesper B
J Clin Immunol; 2022 Apr; 42(3):546-558. PubMed ID: 34989946
[TBL] [Abstract][Full Text] [Related]
19. Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.
Jiang W; Withers B; Sutrave G; Clancy LE; Yong MI; Blyth E
Curr Hematol Malig Rep; 2019 Aug; 14(4):247-260. PubMed ID: 31228095
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and outcome of concurrent and sequential multiviral cytomegalovirus, Epstein-Barr virus, BK virus, adenovirus and other viral reactivations in transplantation.
Sim BZ; Yong KY; Slavin MA; Yong MK
Curr Opin Infect Dis; 2022 Dec; 35(6):536-544. PubMed ID: 36255049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
